Accessibility Statement Skip Navigation
  • PRNewswire.com
  • +971 (0) 4 368 1644
  • GDPR
  • Journalists
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Products
  • General Inquiries
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +971 (0) 4 368 1644 from 8 AM - 5:30 PM GMT

    • Contact
    • Contact

      +971 (0) 4 368 1644
      from 8 AM - 5:30 PM GMT

  • Request More Information
  • Journalists
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Request More Information
  • Journalists
  • GDPR
  • Products
  • Request More Information
  • Journalists
  • GDPR

Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain
  • USA - español
  • Middle East - Arabic
  • USA - Français
  • APAC - Traditional Chinese
  • USA - Deutsch
  • APAC - English


News provided by

European Wellness Biomedical Group

12 May, 2025, 08:11 GMT

Share this article

Share toX

Share this article

Share toX

HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ -- A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof. Mike Chan's longstanding vision of organ-specific, cell-specific regenerative medicine. This pivotal research [1], authored by Prof. Mike Chan and published by Genesis Biomedical Research Institute in collaboration with global universities, represents a transformative leap in precision healthcare, including the complex realm of brain regeneration.

Continue Reading
Prof. Mike Chan reviews a brain replica alongside the landmark Human Cytology Atlas, reflecting on decades of work in targeted organ-and-brain-specific regenerative medicine -- now validated by science. “To heal the brain, we must understand every cell within it,” he says, reaffirming his long-held belief in precision-targeted therapy.
Prof. Mike Chan reviews a brain replica alongside the landmark Human Cytology Atlas, reflecting on decades of work in targeted organ-and-brain-specific regenerative medicine -- now validated by science. “To heal the brain, we must understand every cell within it,” he says, reaffirming his long-held belief in precision-targeted therapy.

The landmark Human Cytology Atlas utilized single-cell RNA sequencing, high-dimensional cytometry, and bioinformatics to classify and quantify human cell types across various organs — including the intricate human brain. This cellular roadmap redefines how therapies must be developed: not generically, but tailored to match specific cell populations within targeted organs.

"While precision medicine has gained widespread recognition, I have always believed that true healing demands an even deeper understanding — acknowledging that every stem cell is inherently unique.

Each of the 400+ human cell types carries distinct molecular blueprints, comprising specific molecules, amino acid sequences, proteins, glycation rates, and transcription factors, all intricately tailored to the organs and tissues they sustain.

This principle has been the cornerstone of my work in developing targeted, brain-and-organ-specific-precursor stem cell bioregenerative therapies," said Prof. Dr. Mike Chan.

"For true regenerative success, A1 must match A1, B6 must match B6, Z10 must match Z10. There are no shortcuts when it comes to restoring the body's natural cellular balance."

The Brain: A Complex Frontier for Cellular Medicine

Among all organs, the brain exemplifies the need for cellular precision. As Prof. Chan noted, "To heal the brain, we must understand every cell within it." The Human Cytology Atlas revealed extraordinary specialization within brain structures such as the frontal lobe, hippocampus, pineal gland, prefrontal cortex, and substantia nigra. Each region contains unique cell types with distinct roles, underlining why regenerative therapies must match the exact cells to the corresponding brain area [2].

Prof. Chan's protocols at European Wellness emphasize this targeted strategy:

  • Frontal lobe neurons for Alzheimer's disease
  • Prefrontal cortex cells for autism
  • Pineal gland cells for sleep disorders
  • Hippocampal neurons for memory and emotional balance
  • Substantia nigra cells for Parkinson's disease

The Atlas's validation of cell diversity confirms that brain regeneration requires organ-specific, cell-specific therapies — reinforcing European Wellness' pioneering approach.

5 Key Breakthroughs from the Human Cytology Study

  1. Over 400 Cell Types Classified: First-ever complete catalog of human cell types with defined biological roles.
  2. Quantitative Mapping of Cells by Organ: Precision data on cell numbers and distribution enables anatomically tailored therapies.
  3. Discovery of Rare Functional Subtypes: New therapeutic targets for repair, immunity, and neuro-regeneration uncovered.
  4. Validation of Organ-Specific Cellular Identity: Proves that stem cells must be matched specifically to organ and tissue type.
  5. Recognition of Variable Regenerative Capacities: Enables smarter, prioritized treatment designs for aging and chronic diseases.

European Wellness: Precision Medicine in Action

For the first time, regenerative medicine has an exact cellular blueprint to follow. Instead of relying on generalized interventions, clinicians can now design therapies that match organ structure and cellular identity — fulfilling a vision Prof. Mike Chan and European Wellness have advocated for over four decades.

European Wellness Biomedical Group continues to be at the forefront of precision regenerative medicine. Through targeted organ-and-brain-specific precursor stem cell therapies, they deliver individualized programs targeting liver disease, cardiac conditions, neurodegenerative disorders, and memory restoration.

References:

[1] Chan MKS, Jambo SA, Jumat MI, Landa F, Saili NS, et al. Human Cytology: Classification and Quantitative Cell Landscape with Numbers, Types and Functional Diversity. J Stem Cell Res. 6(1):1-42.

[2] Mike KS Chan, Mohd Iskandar Jumat*, Florisa Landa, Nur Shafawati Saili, Siti Azmah Jambo, et al. Exploring the Complexity of the Human Brain: Cell Types, Numbers, and Lobar Functions. Am J Biomed Sci & Res. 2025 26(4) AJBSR.MS.ID.003452, 

About European Wellness Biomedical Group

European Wellness is an award-winning biomedical group specializing in advanced targeted organ-and-brain-specific precursor stem cell therapy, anti-aging, and regenerative protocols. The Group operates flagship centers in Germany, Switzerland, Greece, Malaysia and all over Asia.

Photo - https://mma.prnewswire.com/media/2678608/Prof_Mike_Chan_reviews_a_brain_replica_landmark_Human_Cytology.jpg

Modal title

Also from this source

European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan

European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan

European Wellness Biomedical Group (EWBG) has launched a new research initiative focused on Klotho, a protein with transformative potential in...

World's 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets

World's 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets

A groundbreaking new book by Professor Dr. Mike Chan, "STEM CELLS, PEPTIDES & IMMUNOTHERAPY: Handbook on Regenerative Medicine for Animals,"...

المزيد من الإصدارات من هذا المصدر

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Pharmaceuticals

Pharmaceuticals

المزيد من البيانات الصحفية في مواضيع ذات صلة

Contact PR Newswire

  • +971 (0) 4 368 1644
    from 8 AM - 5:30 PM GMT

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+971 (0) 4 368 1644
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.